Parenteral
artesunate for the treatment of severe
malaria in non-immune travelers is associated with late-onset
hemolysis. In children in sub-Saharan Africa, the hematologic effects of
malaria and
artesunate are less well documented. Here we report a prospective case series of 91 children with severe
malaria treated with parenteral
artesunate, managed at a resource-poor hospital in Africa, with longitudinal data on
hemoglobin (Hb),
lactate dehydrogenase (LDH),
haptoglobin, and erythrocyte morphology. The median (range) age was 2 (1-8) years and 43 (47%) were female. The median (IQR) admission Hb level was 69 (55-78) g/L and 20 patients (22%) had severe malarial
anemia (Hb < 50 g/L). During hospitalization, 69 patients (76%) received one or more
blood transfusions. Fatal outcome in 8 patients was associated with severe
anemia in 6/8 cases. Follow-up Hb measurement was performed on 35 patients (38%) at day 14 after initial hospital admission; the remaining patients had no clinical evidence of
anemia at the follow-up visit. The convalescent Hb was median (range) 90 (60-138) g/L, which was significantly higher than the paired admission levels (median increase +28 g/L, p < .001). Evidence of
hemolysis (elevated LDH and low
haptoglobin) was common at admission and improved by day 14. No patient met the standardized definition of post-
artemisinin delayed
hemolysis (PADH). In this cohort of young children with severe
malaria treated with
artesunate,
anemia was common at admission, required one or more transfusions in a majority of patients, and markers of
hemolysis had normalized by day 14.